期刊
MOLECULAR CANCER THERAPEUTICS
卷 21, 期 10, 页码 1499-1509出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-22-0201
关键词
-
类别
资金
- Fundacion Asociacion Espanola contra el Cancer (AECC)
- FERO (EDM)
- Ramon Areces Foundation
- Cellex Foundation
- BBVA (CAIMI)
- ISCIII
- FIS [PI19/00318]
- William K. Bowes Jr Foundation
- German Research Foundation [AB 1234/1-1]
- Office of Biological and Environmental Research of the U.S. Department of Energy Atmospheric System Research Program [DE-SC0000001]
- National Institute of Health Research UK
- UK-China Research and Innovation Partnership Fund through the Met Office Climate Science for Service Partnership (CSSP) China as part of the Newton Fund
- NIH [U12AB123456, R01AB123456]
T-cell bispecific antibodies (TCB) are engineered molecules that can bind both the T-cell receptor and tumor-specific antigens, showing potential therapeutic effects for EGFRvIII mutation in glioblastoma (GBM). We designed and developed a novel EGFRvIII-TCB with specificity and potent antitumor activity, promoting T-cell activation and cytokine secretion for tumor cell killing, as well as T-cell recruitment into tumors. In GBM animal models, including humanized orthotopic patient-derived xenograft models, EGFRvIII-TCB induced tumor regression. These results support the clinical testing of EGFRvIII-TCB.
T-cell bispecific antibodies (TCB) are engineered molecules that bind both the T-cell receptor and tumor-specific antigens. Epider-mal growth factor receptor variant III (EGFRvIII) mutation is a common event in glioblastoma (GBM) and is characterized by the deletion of exons 2-7, resulting in a constitutively active receptor that promotes cell proliferation, angiogenesis, and invasion. EGFR-vIII is expressed on the surface of tumor cells and is not expressed in normal tissues, making EGFRvIII an ideal neoantigen target for TCBs. We designed and developed a novel 2 thorn 1 EGFRvIII-TCB with optimal pharmacologic characteristics and potent antitumor activ-ity. EGFRvIII-TCB showed specificity for EGFRvIII and promoted tumor cell killing as well as T-cell activation and cytokine secretion only in patient-derived models expressing EGFRvIII. Moreover, EGFRvIII-TCB promoted T-cell recruitment into intracranial tumors. EGFRvIII-TCB induced tumor regression in GBM animal models, including humanized orthotopic GBM patient-derived xenograft models. Our results warrant the clinical testing of EGFR-vIII-TCB for the treatment of EGFRvIII-expressing GBMs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据